Showing results (161-170 of 324) with videos related to
Sort By:
Pageof 33
Proceedings of the National Academy of Sciences of the United States of America|November 27, 2015
STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunityOlivier Demaria, Aude De Gassart, Sanja Coso, et al.European Journal of Cancer (Oxford, England : 1990)|May 19, 2015
Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progressionIgor Puzanov, Ravi K Amaravadi, Grant A McArthur, et al.Translational Oncology|June 28, 2017
High-Throughput Screening of Myxoid Liposarcoma Cell Lines: Survivin Is Essential for Tumor GrowthMarieke A de Graaff, Shruti Malu, Irma Guardiola, et al.Journal of Hematology & Oncology|January 1, 2020
Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicineApostolia-Maria Tsimberidou, David S Hong, Jennifer J Wheler, et al.Cancer Communications (London, England)|June 28, 2023
Safety and immunogenicity of a third dose of mRNA-1273 vaccine among cancer patientsAnna Giuliano, Barbara Kuter, Shari Pilon-Thomas, et al.Melanoma Research|July 9, 2011
A phase II study of gefitinib in patients with metastatic melanomaSapna P Patel, Kevin B Kim, Nicholas E Papadopoulos, et al.Cancer Immunology Research|March 22, 2015
BRAFV600E Co-opts a Conserved MHC Class I Internalization Pathway to Diminish Antigen Presentation and CD8+ T-cell Recognition of MelanomaSherille D Bradley, Zeming Chen, Brenda Melendez, et al.JCO Precision Oncology|September 11, 2020
Phase I Study of the BRAF Inhibitor Vemurafenib in Combination With the Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With BRAF-Mutated MalignanciesVivek Subbiah, Shiraj Sen, Kenneth R Hess, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 9, 2015
Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical TrialsAdemi Santiago-Walker, Robert Gagnon, Jolly Mazumdar, et al.Scientific Reports|October 21, 2016
Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinomaPeter Bailey, David K Chang, Marie-Andrée Forget, et al.Pageof 33